Readoutin 76d
Epizyme, Inc. — Tazemetostat
Phase 3 primary completion: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma..
- Date
- Feb 2027
- Type
- Readout
- Indication
- Relapsed/Refractory Follicular Lymphoma